The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer
Official Title: A Single Arm, Open-label, Multicenter, Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer Patients
Study ID: NCT03751592
Brief Summary: This Ib / IIa clinical trial program focuses on the small cell lung cancer (SCLC), Squamous non-small cell lung cancer (NSCLC) and adeniform NSCLC in order to start a better development on the broad-spectrum value of chlorogenic acid: Determine the Disease control rate(DCR)of phase Ib/IIa of Chlorogenic acid for injection in the advanced Lung Cancer Patients.
Detailed Description: 1. Determine the Disease control rate(DCR)of Chlorogenic acid for injection in the advanced Lung Cancer Patients; 2. Determine the Overall Survival(OS)of Chlorogenic acid for injection in the advanced Lung Cancer Patients; 3. Determine the Objective response rate(ORR)of Chlorogenic acid for injection in the advanced Lung Cancer Patients; 4. Determine the Progression Free Survival(PFS)of Chlorogenic acid for injection in the advanced Lung Cancer Patients; 5. Determine Eastern Cooperative Oncology Group(ECOG).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, , China
Name: Yuankai Shi, Dr
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR